Alice Y Zhou1, Daniel Y Wang2, Svetlana McKee3, Fei Ye4, Chun-Che Wen4, Debbie E Wallace5, Kristin K Ancell5, Robert M Conry2, Douglas B Johnson5. 1. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 2. Department of Medicine, Baylor College of Medicine, Houston, Texas. 3. Department of Medicine, University of Alabama, Birmingham, Alabama. 4. Department of Biostatics, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.
Abstract
BACKGROUND AND OBJECTIVES: Patients with in-transit or limited cutaneous metastatic melanoma may benefit from intralesional injections with talimogene laherparepvec (TVEC), a modified oncolytic herpesvirus. However, its use in patients with adverse prognostic scores in a real-life clinical setting has not been studied. METHODS: We performed a two-center retrospective analysis of 40 patients with metastatic melanoma treated with TVEC from 2015-2017. Demographics, overall response, and survival after therapy were noted. RESULTS: Overall, there was a durable response rate of 40%; median progression-free survival (PFS) was 10.5 months and median overall survival (OS) was not reached. Bulky disease was associated with decreased OS (15.7 months vs not reached, P < .05) and mPFS (2.3 months vs not reached, P < .05), when compared with smaller tumors. Poor performance status (ECOG 2-3) was associated with worse OS (10.2 months vs not reached, P < .05) and PFS (2.1 months vs not reached, P < .05) compared to patients with ECOG 0-1. There was no difference in the outcomes with age greater than 75 or with prior therapies. Adverse events were relatively tolerable. CONCLUSIONS: These findings demonstrate that TVEC is an effective and safe treatment for metastatic melanoma in a real-life clinical setting, and suggest parameters to aid in appropriate therapy selection for optimal response.
BACKGROUND AND OBJECTIVES:Patients with in-transit or limited cutaneous metastatic melanoma may benefit from intralesional injections with talimogene laherparepvec (TVEC), a modified oncolytic herpesvirus. However, its use in patients with adverse prognostic scores in a real-life clinical setting has not been studied. METHODS: We performed a two-center retrospective analysis of 40 patients with metastatic melanoma treated with TVEC from 2015-2017. Demographics, overall response, and survival after therapy were noted. RESULTS: Overall, there was a durable response rate of 40%; median progression-free survival (PFS) was 10.5 months and median overall survival (OS) was not reached. Bulky disease was associated with decreased OS (15.7 months vs not reached, P < .05) and mPFS (2.3 months vs not reached, P < .05), when compared with smaller tumors. Poor performance status (ECOG 2-3) was associated with worse OS (10.2 months vs not reached, P < .05) and PFS (2.1 months vs not reached, P < .05) compared to patients with ECOG 0-1. There was no difference in the outcomes with age greater than 75 or with prior therapies. Adverse events were relatively tolerable. CONCLUSIONS: These findings demonstrate that TVEC is an effective and safe treatment for metastatic melanoma in a real-life clinical setting, and suggest parameters to aid in appropriate therapy selection for optimal response.
Authors: Rebecca L Read; Lauren Haydu; Robyn P M Saw; Michael J Quinn; Kerwin Shannon; Andrew J Spillane; Jonathan R Stretch; Richard A Scolyer; John F Thompson Journal: Ann Surg Oncol Date: 2014-09-26 Impact factor: 5.344
Authors: Jason Chesney; Sanjay Awasthi; Brendan Curti; Laura Hutchins; Gerald Linette; Pierre Triozzi; Marcus C B Tan; Russell E Brown; John Nemunaitis; Eric Whitman; Christopher Windham; Jose Lutzky; Gerald F Downey; Nicolas Batty; Thomas Amatruda Journal: Melanoma Res Date: 2018-02 Impact factor: 3.599
Authors: Romany A N Johnpulle; Robert M Conry; Jeffrey A Sosman; Igor Puzanov; Douglas B Johnson Journal: Oncoimmunology Date: 2016-10-18 Impact factor: 8.110
Authors: Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin Journal: J Clin Oncol Date: 2015-05-26 Impact factor: 44.544
Authors: Howard L Kaufman; Robert H I Andtbacka; Frances A Collichio; Michael Wolf; Zhongyun Zhao; Mark Shilkrut; Igor Puzanov; Merrick Ross Journal: J Immunother Cancer Date: 2017-09-19 Impact factor: 13.751
Authors: Emma H A Stahlie; Viola Franke; Charlotte L Zuur; Willem M C Klop; Bernies van der Hiel; Bart A Van de Wiel; Michel W J M Wouters; Yvonne M Schrage; Winan J van Houdt; Alexander C J van Akkooi Journal: Cancer Immunol Immunother Date: 2021-01-28 Impact factor: 6.968
Authors: Anne Fröhlich; Dennis Niebel; Simon Fietz; Eva Egger; Andrea Buchner; Judith Sirokay; Jennifer Landsberg Journal: Cancer Immunol Immunother Date: 2020-02-12 Impact factor: 6.968
Authors: Alexander C J van Akkooi; Sebastian Haferkamp; Sophie Papa; Viola Franke; Andreas Pinter; Carsten Weishaupt; Margit A Huber; Carmen Loquai; Erika Richtig; Priya Gokani; Katarina Öhrling; Karly S Louie; Peter Mohr Journal: Adv Ther Date: 2020-12-26 Impact factor: 3.845
Authors: Josep Malvehy; Igor Samoylenko; Dirk Schadendorf; Ralf Gutzmer; Jean-Jacques Grob; Joseph J Sacco; Kevin S Gorski; Abraham Anderson; Cheryl A Pickett; Kate Liu; Helen Gogas Journal: J Immunother Cancer Date: 2021-03 Impact factor: 13.751
Authors: Johannes Kleemann; Manuel Jäger; Eva Valesky; Stefan Kippenberger; Roland Kaufmann; Markus Meissner Journal: Cancer Manag Res Date: 2021-07-15 Impact factor: 3.989